Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody (2022)
Journal Article
Greiner, J., Goetz, M., Schuler, P. J., Bulach, C., Hofmann, S., Schrezenmeier, H., …Guinn, B. A. (2022). Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. British journal of haematology, 198(5), 866-874. https://doi.org/10.1111/bjh.18326

Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and is often associated with a favourable prognosis. Immune responses play an increasing role in AML treatment decisions; however, the role of immune checkpoint inhibition is stil... Read More about Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.

Inhibition of arginine methylation impairs platelet function (2021)
Journal Article
Marsden, A. J., Riley, D. R. J., Barry, A., Khalil, J. S., Guinn, B. A., Kemp, N. T., …Beltran-Alvarez, P. (in press). Inhibition of arginine methylation impairs platelet function. ACS Pharmacology & Translational Science, https://doi.org/10.1021/acsptsci.1c00135

Protein arginine methyltransferases (PRMTs) catalyze the transfer of methyl groups to arginine residues in proteins. PRMT inhibitors are novel, promising drugs against cancer that are currently in clinical trials, which include oral administration of... Read More about Inhibition of arginine methylation impairs platelet function.